Blood pressure screening rose sharply as a Nigerian quality program closed gaps in pregnancy care
Hypertensive disorders of pregnancy remain a major driver of maternal and perinatal death in Nigeria, and the burden does not stop at delivery. Hypertensive disorders of pregnancy also mark a woman’s future cardiovascular risk, making every missed blood pressure check a lost opportunity for prevention as well as diagnosis. In two Nigerian states, a quality improvement program tried to tighten that gap across antenatal, postnatal, and family planning services, where pregnant and postpartum women already interact with the health system and can be screened without creating a separate pathway of care.
The program ran from 2019 through 2022 in the Federal Capital Territory and Lagos State, and it targeted prevention, early detection, and management of HDP together with related risk factors such as anemia and diabetes. Forty public and private facilities participated in the broader implementation effort. Facility-based assessment work in 20 facilities examined provider knowledge and practice around antenatal diagnosis and management, and the findings showed clear weaknesses in knowledge, self-reported confidence, and observed adherence to best practices. In other words, the intervention was not starting from a strong baseline. It had to change day-to-day clinical behavior before it could change outcomes.
Antenatal care moved from inconsistent screening to routine measurement
The clearest signal came from antenatal care. Among 93,384 antenatal visits across program facilities, the median proportion of women who received a blood pressure check rose from 44% at baseline to 89% in the final six months of the program. Screening for anemia increased from 48% to 91%, and diabetes checks climbed from 32% to 87%. Those shifts are clinically important because blood pressure measurement is the gateway test for detecting chronic hypertension, gestational hypertension, preeclampsia, and eclampsia, while anemia and diabetes can compound pregnancy risk and complicate both maternal and fetal outcomes.
A one-time clinic encounter does not protect a pregnant woman from preeclampsia. Repeated screening does.
The jump in antenatal screening suggests the program did more than increase awareness. It appears to have embedded screening into workflow, which is where quality improvement usually succeeds or fails. Blood pressure checks in pregnancy are not technically complex, but they depend on supplies, staff confidence, documentation habits, and a consistent expectation that no woman should leave a visit without a measured vital sign. When those elements align, hypertension is more likely to be recognized before severe features emerge.
Postnatal and family planning visits became new points of cardiovascular surveillance
The program also extended screening beyond pregnancy, where many systems traditionally lose contact with women at risk. From January 2021 to December 2022, the median proportion of 57,658 postnatal care visits with a documented blood pressure check increased from 81% at baseline to 90% in the final six months. During the same period, the median proportion of 105,237 family planning visits with a blood pressure check increased from 73% to 98%.
That family planning gain matters because postpartum women do not always return through maternal health clinics, yet they remain vulnerable to persistent hypertension and to the long-term cardiovascular consequences linked to a history of preeclampsia and related disorders. Family planning encounters are often frequent, practical, and less fragmented than specialty follow-up, which makes them a sensible place to continue surveillance. The same logic applies to postnatal care, where a blood pressure reading can identify women whose pregnancy complication has not resolved or whose hypertension has become chronic.
By moving screening into these routine touch points, the program treated hypertension as a continuum rather than a single obstetric event. That approach fits the biology. Pregnancy-related hypertension can reflect endothelial dysfunction, vascular injury, and systemic inflammation that do not disappear at delivery. When the health system checks blood pressure only during late pregnancy, it misses both persistent disease and the transition into long-term cardiovascular risk.
Provider knowledge gaps shaped the need for system-level change
The facility assessment in 20 centers found important gaps in provider knowledge, confidence, and observed practice around HDP and risk factor management. Those deficits help explain why quality improvement had room to move the numbers so substantially. A screening program can only perform as well as the people who deliver it, and in this setting the baseline picture suggested that training alone was not enough unless it was paired with process changes, supervision, and a clearer expectation that screening belonged in every relevant visit.
This is the practical lesson from the program’s design. The intervention did not focus only on one clinic type or one disease label. It operated across antenatal, postnatal, and family planning services, which is where women with reproductive-age cardiovascular risk actually show up. The breadth of those touch points gives the program its clinical strength, because it reduces dependence on a single entry point and makes blood pressure surveillance more likely to survive staff turnover, clinic congestion, and the uneven rhythms of maternal care.
Maternal survival and future cardiovascular risk sit on the same pathway
Nigeria carries a high burden of maternal mortality and morbidity from hypertensive disorders, and the stakes extend beyond childbirth. Women who develop HDP face higher risk for future cardiovascular disease, including premature cardiovascular mortality. A quality improvement program that increases detection of hypertension, anemia, and diabetes during routine care is therefore not just an obstetric intervention. It is also an upstream cardiovascular prevention strategy aimed at women of reproductive age.
The findings do not show downstream clinical outcomes such as reduced eclampsia, fewer maternal deaths, or fewer cardiovascular events, and they do not claim more than improved screening and process performance. Even so, the magnitude of change across a large number of visits is hard to ignore. In settings where blood pressure is missed as often as it is measured, raising screening to the high 80s and 90s can change the odds of early recognition, timely referral, and treatment initiation.
The final implication is straightforward: when health systems make routine surveillance part of normal maternal and reproductive care, they create a better chance of catching disease before it becomes an emergency. The unanswered question is whether these process gains can be sustained at scale and linked to hard maternal and cardiovascular outcomes over time.